FULCRUM THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
FULCRUM THERAPEUTICS, INC. (FULC) had Debt Securities, Available-for-sale, Amortized Cost of $270.94 million as of 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-09-02
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $270.94M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $283.57M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $154.60M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $153.33M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $270.94M S-4 · filed 2026-09-02 |
| 2026-03-31 | $283.57M 10-Q · filed 2026-04-27 |
| 2025-12-31 | $154.60M S-4 · filed 2026-09-02 |
| 2025-09-30 | $153.33M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $171.44M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $184.35M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $182.68M S-4 · filed 2026-09-02 |
| 2024-09-30 | $184.23M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $187.44M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $173.80M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $210.79M 10-K · filed 2025-02-25 |
| 2023-09-30 | $227.89M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $245.40M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $263.76M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $168.62M 10-K · filed 2024-02-27 |
| 2022-09-30 | $131.77M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $129.89M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $162.89M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $183.15M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | $174.96M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $68.78M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $43.12M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $55.86M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | $41.77M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $55.94M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $55.88M 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |